Alivus Life Sciences Ltd

Alivus Life Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Alivus Life Sciences Ltd

₹ 1,111 -2.91%
20 May - close price
glenmarklifesciences.com BSE: 543322 NSE: ALIVUS
About

Glenmark Life Sciences, a subsidiary of Nirma Limited, a diversified conglomerate with interest in consumer products, cement, chemicals and pharmaceuticals. It is a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas. The company further operates in Contract Development and manufacturing operations to offer services to specialty Pharmaceutical companies.

Key Points

History
Before 2019 API business was an integral part of Glenmark Pharma (GPL). It was separated from GPL into GLS through a Business Transfer Agreement in Jan 2019, and GLS was subsequently listed on NSE & BSE in FY22. [1]

Website BSE NSE
  • Market Cap ₹ 13,627 Cr.
  • Current Price ₹ 1,111
  • High / Low ₹ 1,335 / 755
  • Stock P/E 28.1
  • Book Value ₹ 230
  • Dividend Yield 2.02 %
  • ROCE 25.1 %
  • ROE 18.9 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 60.5%

Cons

  • The company has delivered a poor sales growth of 9.20% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Part of BSE Healthcare Nifty 500 BSE SmallCap BSE Allcap Nifty MidSmallcap 400

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
514 490 509 541 621 578 595 573 537 589 507 642 650
372 343 366 395 415 385 428 400 395 429 373 452 451
Operating Profit 142 147 144 145 206 193 167 173 141 159 134 190 198
OPM % 28% 30% 28% 27% 33% 33% 28% 30% 26% 27% 27% 30% 31%
5 9 10 7 3 2 5 2 3 5 9 10 10
Interest 0 0 0 0 0 0 0 0 0 0 0 0 1
Depreciation 10 10 10 11 12 13 13 13 15 14 15 15 16
Profit before tax 138 146 144 141 198 182 159 161 130 150 127 185 191
Tax % 28% 26% 26% 26% 26% 26% 25% 26% 24% 26% 25% 26% 26%
99 109 107 105 146 135 119 119 98 111 95 137 142
EPS in Rs 8.07 8.87 8.72 8.57 11.95 11.05 9.69 9.69 7.99 9.10 7.78 11.18 11.58
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
0 886 1,537 1,885 2,123 2,161 2,283 2,387
0 638 1,064 1,294 1,506 1,518 1,608 1,704
Operating Profit -0 248 473 592 617 643 675 683
OPM % -4% 28% 31% 31% 29% 30% 30% 29%
0 -0 11 0 14 28 11 35
Interest 0 1 34 88 28 1 2 2
Depreciation 0 19 29 33 38 42 53 61
Profit before tax -0 228 421 471 565 629 631 654
Tax % 4,200% 14% 26% 25% 26% 26% 25% 26%
-0 196 313 352 419 467 471 486
EPS in Rs -430.00 997.86 1,597.37 358.74 34.17 38.11 38.43 39.63
Dividend Payout % 0% 0% 0% 0% 61% 110% 59% 13%
Compounded Sales Growth
10 Years: %
5 Years: 9%
3 Years: 4%
TTM: 5%
Compounded Profit Growth
10 Years: %
5 Years: 9%
3 Years: 5%
TTM: 3%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: 35%
1 Year: 35%
Return on Equity
10 Years: %
5 Years: 25%
3 Years: 21%
Last Year: 19%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 0.01 2 2 2 25 25 25 25
Reserves -1 86 400 751 2,030 2,114 2,308 2,793
0 0 0 0 3 19 17 57
1 1,387 1,324 1,244 414 545 501 537
Total Liabilities 0 1,475 1,726 1,997 2,471 2,702 2,850 3,411
0 456 546 573 590 781 805 963
CWIP 0 80 11 14 97 62 106 94
Investments 0 0 0 0 0 0 0 478
0 939 1,169 1,410 1,784 1,860 1,939 1,877
Total Assets 0 1,475 1,726 1,997 2,471 2,702 2,850 3,411

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
-0 10 195 388 598 306 414 392
0 -9 -51 -69 -122 -147 -116 -616
0 1 -137 -214 -79 -388 -279 -6
Net Cash Flow 0 2 8 106 397 -228 18 -230

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 44 185 152 120 116 136 122 148
Inventory Days 162 441 227 214 185 224 251 228
Days Payable 41 201 111 92 110 158 139 132
Cash Conversion Cycle 165 424 268 241 190 202 235 244
Working Capital Days -2,059 -186 -37 12 150 177 188 275
ROCE % 529% 186% 97% 42% 30% 28% 25%

Shareholding Pattern

Numbers in percentages

Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
82.85% 82.85% 82.85% 82.85% 82.85% 82.85% 82.85% 82.85% 82.85% 75.00% 75.00% 74.99%
7.58% 6.04% 4.45% 3.28% 3.27% 4.39% 4.57% 5.01% 4.81% 7.85% 6.74% 6.57%
0.79% 0.79% 0.08% 0.00% 0.58% 0.64% 0.74% 1.41% 1.57% 4.16% 4.86% 5.19%
8.78% 10.31% 12.62% 13.86% 13.30% 12.13% 11.84% 10.73% 10.76% 12.99% 13.40% 13.25%
No. of Shareholders 2,33,5382,32,2032,25,7302,22,8662,08,2671,98,7641,85,5311,56,1831,49,3961,43,9601,46,8401,41,977

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls